From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, introduces the key trials in progress at her center, including a treatment allocation study for patients with muscle-invasive localized bladder cancer, which features a combination of cystoscopy and tumour genomics to reduce the number of patients undergoing cystectomy. In addition, Dr Plimack also highlights a trial testing the combination of nivolumab and axitinib for kidney cancer (NCT03172754). Finally, she discusses a study looking to sensitize bladder cancer patients that are refractory to PD-1 inhibiton using guadecitabine (NCT03179943).
A bladder-sparing approach for muscle-invasive bladder cancer
